Four in five docs support ad moratorium

Share this article:
Over 80 percent of physicians surveyed believe it is a good idea to prohibit DTC advertising for new prescription drugs for a period of time after the FDA approval to allow doctors time to gain familiarity with the medications, according to a recent study.
Research firm HRA conducted the study by surveying 2,015 physicians in their analysis.
While more than four out of five physicians favored some type of ban on DTC for all new prescription drugs, there was less agreement on the type of ban that they would be most likely to support.
Forty-three percent favor a mandatory ban for some limited period of time. Thirty-three percent favor a voluntary ban with each pharmaceutical company deciding when to begin advertising to consumers, and 24 percent say no ban on DTC advertising is necessary.
Other key findings of the survey included:
•Fifty-six percent of the doctors noted that they get one to five calls a week to discuss DTC-advertised drugs or schedule an appointment to discuss a DTC-advertised drug.
•Sixty-five percent of the doctors stated that patients initiate discussions about DTC-advertised prescription drug products. 
•Sixty-four percent of the physicians get one to five patient requests per week for DTC-advertised drugs.
•Nearly two-thirds, 62 percent, of the surveyed doctors stated that they prescribe the discussed medication only one-quarter of the time or less, with nearly 40 percent of those writing a prescription 10 percent, or less, of the time.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.